Tony Hagen


ASCO Identifies Additional Ways to Improve Hazardous Drug Safety

February 24th 2020

The United States Pharmacopeial Convention (USP) General Chapter is a good start for improving the protection of healthcare workers exposed to hazardous drugs, but more studies and safety protocols are needed, according to an American Society of Clinical Oncology (ASCO) expert panel that evaluated USP and various other guidelines in a report last year.

Practices Make Surprise Decision on OCM Risk

January 30th 2020

Many practices enrolled in the Oncology Care Model were expected to drop out of the value-based model rather than take on 2-sided risk, which would entail upside and downside financial exposure.

T-Cell Immunotherapy Pioneer Seeks New Direction for Solid Tumors

January 11th 2020

CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors.

Pazdur Followed the Pathway of Greatest Resistance to the FDA

December 30th 2019

Richard Pazdur, MD, set out to be a leader in medicine and a teacher of doctors. He achieved that and more, turning the oncology drugs section of the FDA from a poorly understood and lead-footed division into a fast-moving and patient-responsive entity.

NGS Testing Is Essential Before Induction in NSCLC

November 12th 2019

Suresh S. Ramalingam, MD, FASCO, highlights current and emerging therapies for 6 key actionable driver mutations in non–small cell lung cancer.

Neoadjuvant Approaches Showcase Advantages in NSCLC

November 10th 2019

Based on efficacy, tolerability, and practicality, neoadjuvant therapy in lung cancer offers significant advantages over adjuvant treatment, said Jamie E. Chaft, MD, in a presentation during the 14th Annual New York Lung Cancers Symposium®. However, she added, adjuvant treatment predominantly remains the standard of care at many cancer centers, she said.

CMS Proposes a Next-Generation Oncology Care Model

November 4th 2019

With just 2 more years to go in the Oncology Care Model, CMS is proposing a next-generation payment system that would include more private payers and hold practices more accountable for quality and costs of care.

IBM Seeks Niche for Watson for Oncology

October 15th 2019

The artificial intelligence system that IBM designed for oncology has demonstrated clinical utility in recent studies, generating excitement that the technology may have a role as a decision support tool.

CFS&reg Experts: Novel Therapies and Onco-Genomics Add Heft to Precision Medicine

October 2nd 2019

Co-chairs William K. Oh, MD, Adam M. Brufsky, MD, PhD, and Benjamin P. Levy, MD, preview key topics that will be covered at the 37th Annual CFS®: Innovative Cancer Therapy for Tomorrow symposium.

Andre Goy: Giving Patients Strength to Fight

September 20th 2019

Andre Goy, MD, MS, discusses cutting-edge CAR T-cell therapy and other groundbreaking investigations, as well as his thoughts on general developments in oncology and hematology.